Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic

Eisbach Bio GmbH announced the receipt of a Texas Therapeutics Company Award from the Cancer Prevention and Research Institute of Texas (CPRIT). This prestigious grant of US $4.75 million will support the clinical development of Eisbach’s first-in-class allosteric small molecule inhibitor EIS-12656 targeting ALC1.